Drug Eluting Balloons Market Expected to Grow at a CAGR of 8.1% by 2028 | Medtronic, Becton, Boston Scientific

Drug Eluting Balloons Market

SEATTLE, USA, Jan. 17, 2022 / EINPresswire.com/ — New study “Drug Eluting Balloons Market 2022 Analysis by Market Trends (Drivers, Restraints, Opportunities, Threats, Challenges & Opportunities) ‘Investment), Size, Share and Outlook’ has been added to Coherent Market Insights.

A drug-eluting balloon, also known as a drug-coated balloon, is a stentless technology in which effective homogeneous delivery of anti-proliferative drugs is handled through the vessel wall through an inflated balloon. Drug-eluting balloons have also been studied in clinical trials to prevent in-stent restenosis of the coronary artery. These balloons evenly deliver drugs into the vessel and prevent neointimal hyperplasia.

𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐭𝐡𝐢𝐬 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 @ 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 @ @ https://www.coherentmarkettinsights.com/insight/request-sample/2459

Driver:

Market players are focusing on launching new drug eluting balloons to address critical unmet patient needs and treat coronary heart disease and other diseases, driving the growth of the global drug eluting balloon market. For example, in July 2016, Medtronic received FDA approval for the IN.PACT Admiral drug-coated balloon (DCB) to provide greater treatment options for long lesions in patients with arterial disease. device (MAP).

Additionally, in 2014, the Food and Drug Administration (FDA) approved CR Bard’s drug-coated balloon Lutonix 035 (Lutonix DCB), a technology that can reduce restenosis in vessels treated with balloon angioplasty. This technology is approved for use in femoral and popliteal arteries when affected by peripheral arterial disease (PAD).

Key players:

The major players operating in the global drug eluting flasks market are Medtronic, Biotronik, Surmodics, Terumo Corporation, Opto Circuits Limited, Koninklijke Philips NV, B. Braun Melsungen AG, Cook Medical, Boston Scientific Corporation and Becton, Dickinson and Company (BD) .

In November 2016, Spectranetics Corporation announced that it had submitted its premarket approval (PMA) application to the FDA for the drug-coated angioplasty balloon Stellarex (DCB); designed to restore and maintain blood flow to the superficial femoral and popliteal arteries in patients with peripheral arterial disease (PAD).

𝐁𝐮𝐲 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐎𝐟𝐟 𝟐𝟎𝟎𝟎 𝐎𝐟𝐟 𝐎𝐟𝐟 𝐎𝐟𝐟 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐎𝐟𝐟 𝐎𝐟𝐟 𝐎𝐟𝐟 𝐎𝐟𝐟 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐎𝐟𝐟 𝐎𝐟𝐟 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐎𝐟𝐟 𝐎𝐟𝐟 𝐎𝐟𝐟 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐑𝐞𝐩𝐨𝐫𝐭𝐑𝐞𝐩𝐨𝐫𝐭
https://www.coherentmarketinsights.com/insight/buy-now/2459

The research objectives for this report are:

· The SWOT analysis focuses on the major global manufacturers to define, assess and analyze the market competition. By type, application, and region, the market is defined, described, and forecast.
Examine the main global and regional market potential and benefits, opportunities and challenges, restraints and risks.
· Determine whether trends and factors are driving or restraining market growth.
· By identifying high growth categories, stakeholders would be able to analyze market potential.
· Conduct strategic study of growth trends and market contribution of each sub-market.
· Expansions, agreements, new product launches and market acquisitions are all examples of competitive developments.
· Create a strategic profile of key players and thoroughly analyze their growth plans.

Mr Shah
Consistent market information
+1 2067016702
write to us here
Visit us on social media:
Facebook
Twitter
LinkedIn